Application of herba siegesbeckiae composition in preparation of product for improving heart FTO expression level

The expression of cardiac FTO and AMPK pathway-related genes are improved through the shiji composition, which solves the problem of cardiac toxicity in tumor patients, expands the application of shiji formula in cardiac protection, and improves the heart failure induced by doxorubicin .

CN119033840APending Publication Date: 2024-11-29DONGZHIMEN HOSPITAL OF BEIJING UNIV OF CHINESE MEDICINE
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411040708.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

When tumor patients receive anti-tumor treatment, the high incidence and mortality rate are high due to cardiotoxicity. It is difficult for the existing technology to effectively prevent and treat cardiotoxicity caused by anthracycline drugs such as doxorubicin, and the functional target of the qi prescription The efficacy and mechanism of the drug are not completely clear, and the scope of application is limited.

Method used

Provided is a composition of stilbene stilbene, containing 38 to 42 parts of Astragalus, 8 to 12 parts of stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene stilbene Expression level, prepared as a pharmaceutical preparation, including tablets, capsules, granules, oral liquids or injections.

Benefits of technology

By regulating the FTO/AMPK signaling pathway and its downstream molecules, the shiji prescription can improve heart failure induced by doxorubicin, expand its application range in cardiac protection, and significantly improve the FTO, AMPK and its downstream keys in myocardial tissues. protein and mRNA levels of enzymes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033840A_ABST
    Figure CN119033840A_ABST
Patent Text Reader

Abstract

The invention relates to the field of biological medicine, in particular to an application of a siegestistilbene composition in preparation of a product for improving the heart FTO expression level. The molecular mechanism of the herba siegesbeckiae prescription for treating HF is explored, and it is found that the herba siegesbeckiae prescription can improve expression of FTO in myocardial tissue of an HF mouse induced by Dox and improve protein and mRNA levels of AMPK and molecules of downstream key enzymes GLUT4, PFKFB3, CPT1A and the like at the same time, which indicates that the herba siegesbeckiae prescription can improve the HF induced by the Dox by regulating and controlling FTO / AMPK signal channels and downstream molecules of the FTO / AMPK signal channels. The research proves that the herba siegesbeckiae and stilbene formula can improve the CHF induced by adriamycin by regulating the FTO / AMPK pathway, and the application range of the herba siegesbeckiae and stilbene formula is expanded.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to an application of a Siegesbeckia oxyphylla composition in the preparation of a product for improving the expression level of cardiac FTO. Background Art

[0002] The high morbidity and mortality of cancer patients due to cardiotoxicity caused by anticancer drugs cannot be ignored. The most common chemotherapy drugs that induce cardiotoxicity in clinical practice are anthracyclines, with doxorubicin (Dox) as the main representative drug. The effectiveness of their treatment is limited by cumulative cardiotoxicity. Prevention and treatment of cardiotoxicity caused by anticancer drugs is a challenge faced by oncologists and cardiologists.

[0003] The fat mass and obesity associated gene (FTO) has been shown to be involved in the proliferation, apoptosis, migration, invasion and other processes of tumor cells, playing an important role in promoting tumors; interestingly, FTO also plays an important role in cardiac homeostasis and failure, but in contrast to its role in tumors, the expression of FTO in the mouse heart is significantly decreased during heart failure (HF), and the level of N6-methyladenosine (m6A) is significantly increased. Overexpression of FTO can alleviate cardiac dysfunction and improve myocardial remodeling. However, it is not completely clear which genes are affected by FTO-mediated m6A methylation and which pathophysiological processes lead to cardiac damage.

[0004] In previous studies, our team has demonstrated the efficacy of Xijiaqi prescription in various models of heart failure induced in mice, and it also has a certain preventive effect on Dox-induced cardiotoxicity.

[0005] However, the functional targets and pharmacodynamic mechanisms of Xijiaqi prescription are still not fully understood, and its scope of application is limited. Summary of the invention

[0006] Based on this, the present invention provides the use of a Siegesbeckia composition in the preparation of a product for improving the expression level of cardiac FTO, wherein the Siegesbeckia composition is prepared from 38 to 42 parts by mass of Astragalus, 8 to 12 parts by mass of Siegesbeckia herb and 2 to 3 parts by mass of Perennial Herb.

[0007] In one embodiment, increasing the expression level of cardiac FTO includes increasing the mRNA level of FTO and increasing the protein level of FTO.

[0008] In one embodiment, the Siegesbeckia composition is prepared from 40 parts by weight of Astragalus, 10 parts by weight of Siegesbeckia herb and 2.5 parts by weight of Perennial Herb.

[0009] The present invention also provides the use of the above-mentioned Siegesbeckia oxyphylla composition in preparing a product for improving the expression level of cardiac AMPK pathway-related genes, wherein the AMPK pathway-related genes are one or more of AMPK, GLUT4 and PFKFB3.

[0010] In one embodiment, the Siegesbeckia azedarach composition increases the expression level of the AMPK pathway-related gene by increasing the expression level of cardiac FTO.

[0011] In one embodiment, increasing the expression level of cardiac AMPK pathway-related genes includes increasing the mRNA level of the AMPK pathway-related genes and increasing the protein level of the AMPK pathway-related genes.

[0012] In one embodiment, the product is a pharmaceutical preparation.

[0013] In one embodiment, the pharmaceutical preparation comprises a pharmaceutically acceptable excipient.

[0014] In one embodiment, the dosage form of the pharmaceutical preparation is tablets, capsules, granules, oral solution or injection.

[0015] The beneficial effects of the present invention are:

[0016] This paper explores the molecular mechanism of Xijiaqi Fang in treating HF and finds that Xijiaqi Fang can increase the expression of FTO in the myocardial tissue of Dox-induced HF mice, and at the same time increase the protein and mRNA levels of AMPK and its downstream key enzymes GLUT4, PFKFB3, CPT1A and other molecules, indicating that Xijiaqi Fang can improve Dox-induced HF by regulating the FTO / AMPK signaling pathway and its downstream molecules. This study proves that Xijiaqi Fang can improve doxorubicin-induced CHF by regulating the FTO / AMPK pathway, expanding the scope of application of Xijiaqi Fang. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0018] Figure 1The results of the experiment in Example 1 show that the Xijiaqi prescription activates the FTO / AMPK signaling pathway to improve Dox-induced HF in mice; wherein A is a representative Western blot image of the protein in the myocardial tissue of each group of mice; B is the relative expression of FTO protein in the myocardial tissue of each group of mice; C is the relative expression of AMPK protein in the myocardial tissue of each group of mice; D is the relative expression of GLUT4 protein in the myocardial tissue of each group of mice; E is the relative expression of PFKFB3 protein in the myocardial tissue of each group of mice; F is the relative expression of CPT1A protein in the myocardial tissue of each group of mice;

[0019] Figure 2 These are the experimental results related to the improvement of the mRNA expression level of FTO / AMPK pathway related molecules in the myocardial tissue of Dox-induced HF mice by the Xijiaqi prescription in Example 1; wherein A is the relative expression level of FTO mRNA in the myocardial tissue of each group of mice; B is the relative expression level of AMPK mRNA in the myocardial tissue of each group of mice; C is the relative expression level of GLUT4 mRNA in the myocardial tissue of each group of mice; D is the relative expression level of PFKFB3 mRNA in the myocardial tissue of each group of mice; E is the relative expression level of CPT1A mRNA in the myocardial tissue of each group of mice;

[0020] Figure 3 The experimental results of the down-regulation of AMPK and its downstream key enzymes GLUT4, PFKFB3, and CPT1A mRNA expression in H9c2 cardiomyocytes by Dox in Example 2; wherein A is the relative expression of AMPK mRNA in myocardial tissue of each group of mice; B is the relative expression of GLUT4 mRNA in myocardial tissue of each group of mice; C is the relative expression of PFKFB3 mRNA in myocardial tissue of each group of mice; D is the relative expression of CPT1A mRNA in myocardial tissue of each group of mice;

[0021] Figure 4 The experimental results of the down-regulation of AMPK and its downstream key enzyme protein expression in H9c2 cardiomyocytes by Dox in Example 2; wherein A is a representative Western blot image of the protein in the myocardial tissue of each group of mice; B is the relative expression of AMPK protein in the myocardial tissue of each group of mice; C is the relative expression of GLUT4 protein in the myocardial tissue of each group of mice; D is the relative expression of PFKFB3 protein in the myocardial tissue of each group of mice; E is the relative expression of CPT1A protein in the myocardial tissue of each group of mice;

[0022] Figure 5 The experimental results of FTO gene knockdown in Example 2 inhibiting the activation of AMPK in H9c2 cardiomyocytes; A is the effect of FTO gene knockdown on FTO protein expression in H9c2 cardiomyocytes, and B is the effect of FTO gene knockdown on AMPK protein expression in H9c2 cardiomyocytes;

[0023] Figure 6 These are the experimental results related to the upregulation of Dox-induced reduction of AMPK expression in H9c2 cardiomyocytes by overexpression of FTO in Example 2; wherein A is a representative Western blot of AMPK protein in myocardial tissue of each group of mice, and B is the relative expression level of AMPK protein in myocardial tissue of each group of mice. DETAILED DESCRIPTION

[0024] References to embodiments of the present invention will now be provided in detail, one or more examples of which are described below. Each example is provided as an explanation rather than a limitation of the present invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made to the present invention without departing from the scope or spirit of the present invention. For example, a feature illustrated or described as part of one embodiment may be used in another embodiment to produce a further embodiment.

[0025] Therefore, it is intended that the present invention covers such modifications and variations that fall within the scope of the appended claims and their equivalents. Other objects, features and aspects of the present invention are disclosed in or are obvious from the following detailed description. Those of ordinary skill in the art will appreciate that this discussion is only a description of exemplary embodiments and is not intended to limit the broader aspects of the present invention.

[0026] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments, but the embodiments do not limit the present invention in any form. For those skilled in the art, any other changes, modifications, substitutions, combinations, and simplifications made without departing from the spirit and principle of the present invention should all be equivalent replacement methods and are included in the protection scope of the present invention.

[0027] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0028] Example 1

[0029] 1 Experimental Materials

[0030] 1.1 Experimental animals

[0031] Seventy SPF-grade C57BL / 6J male mice, 6 weeks old, weighing 20-25 g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. (Experimental Animal License No.: SCXK(Beijing)2020-0013) and housed in separate cages in the SPF-grade laboratory of the Experimental Animal Center of Beijing University of Chinese Medicine. The animal experiments were approved by the Experimental Animal Ethics Committee of Beijing University of Chinese Medicine, with the ethics review approval number: BUCM-2023041707-2104.

[0032] 1.2 Drugs and reagents

[0033] The drug composition of Xijiaqi prescription (XJQ) is: 10g of Siegesbeckia herb, 2.5g of Perennial Perilla Cortex, and 40g of Astragalus. The Chinese herbal medicine pieces were purchased from Dongzhimen Hospital of Beijing University of Chinese Medicine.

[0034] The general reagents are shown in the following table, and other required reagents are also conventional commercially available products.

[0035]

[0036]

[0037] 2 Experimental methods

[0038] 2.1 Solution preparation

[0039] 2.1.1 Preparation of doxorubicin solution

[0040] 25 mg of Dox was dissolved in 50 mL of 0.9% saline for injection to prepare a 0.5 mg / mL Dox solution.

[0041] 2.1.2 Preparation of Xijiaqi Decoction Solution

[0042] Xijiaqi prescription (XJQ) is composed of 40g of Astragalus, 10g of Siegesbeckia, and 2.5g of Perennial Herb, with each dose containing 52.5g of crude drugs. Soak the herbs in advance for one hour, add 8 times the amount of distilled water, boil the water and turn to low heat for 40 minutes, pour out the first decoction, add 4 times the amount of distilled water for a second decoction, and filter the residue after the water boils for 30 minutes, and combine the two decoctions.

[0043] The conversion coefficient of the dose per kilogram of body weight for adults and mice is 9.1. The daily dose for normal adults is 52.5g. Calculated based on an adult weight of 60kg, the daily dose per kilogram of body weight for adults is 52.5 / 60=0.875g / kg / d. Taking the daily dose of adults as the low-dose group, the low-dose group for mice should be: 0.875*9.1=7.9625g / kg / d, and the medium-dose group and high-dose group are 2 times and 4 times of the low-dose group, respectively. Finally, the low, medium, and high-dose groups of mice are: 7.9625g / kg / d, 15.925g / kg / d, and 31.85g / kg / d, respectively.

[0044] 2.1.3 Preparation of trimetazidine solution

[0045] 30 mg of trimetazidine (TMZ) was dissolved in 20 mL of deionized water to prepare a trimetazidine solution with a concentration of 1.5 mg / kg, which was administered intragastrically.

[0046] 2.2 Animal modeling, grouping and drug administration

[0047] C57BL / 6J male mice were injected intraperitoneally with 5 mg / kg Dox once a week for 4 consecutive weeks, with a cumulative dose of 20 mg / kg. The success of the model was judged by echocardiography, with LVEF ≤ 50% as the standard for successful modeling.

[0048] The mice were randomly divided into blank control group (Control), model group (Dox), low-dose Xijiaqi Fang group (Dox+XJQ-L), medium-dose Xijiaqi Fang group (Dox+XJQ-M), high-dose Xijiaqi Fang group (Dox+XJQ-H) and trimetazidine group (Dox+TMZ) by random number table method, and samples were collected 4 weeks after intragastric administration.

[0049] (1) Control group: deionized water was gavaged once a day for 4 weeks.

[0050] (2) Dox group: Doxorubicin solution was gavaged once a day for 4 weeks.

[0051] (3) Dox+XJQ-L group: Xijiaqi prescription (7.9625 g / kg / d) was administered orally for 4 consecutive weeks.

[0052] (4) Dox+XJQ-M group: Xijiaqi prescription (15.925 g / kg / d) was administered orally for 4 consecutive weeks.

[0053] (5) Dox+XJQH group: Xijiaqi prescription (31.85 g / kg / d) was administered orally for 4 consecutive weeks.

[0054] (6) Dox+TMZ group: trimetazidine (15 mg / kg / d) was administered intragastrically for 4 consecutive weeks.

[0055] 2.3 Mouse sampling

[0056] After intraperitoneal injection of sodium pentobarbital to anesthetize mice, venous blood was collected by eyeball extraction and placed in a 1.5 mL EP tube. The chest cavity was then quickly opened, and the fresh heart was cut. Part of the heart was fixed with a 4% paraformaldehyde solution, and part of the heart was placed in a cryotube and quickly frozen in liquid nitrogen, and then stored in a -80°C refrigerator. The blood was centrifuged at 3000 r / min for 20 minutes, and the upper serum was collected and stored in a -80°C refrigerator for testing.

[0057] 2.4WB

[0058] (1) Total protein extraction: prepare lysis buffer (RIPA: protease phosphoinhibitor: PMSF = 100:1:1) according to the ratio, add to tissues or cells, homogenize (tissue) or ultrasonically disrupt (cells) on ice, and then stand on ice for 20 min to allow for sufficient lysis; precool the centrifuge at 12,000 rpm, 4°C, for 15 min, and collect the supernatant.

[0059] (2) Prepare BCA working solution: Total amount of BCA working solution = (number of standard samples + number of unknown samples) * number of replicate wells * volume of BCA working solution for each sample. Solution A: Solution B = 50:1, mix thoroughly. Add 200 μL of working solution to each well.

[0060] (3) Quantitative detection: Add 25 μL of the diluted BSA standard and the protein sample to be tested to the wells of a 96-well microplate. The concentration of the sample should be diluted 5 or 10 times in advance. Add 200 μL of BCA working solution to each well, mix thoroughly, cover the 96-well plate, incubate at 37°C for 30 minutes, cool to room temperature, and complete the detection within 3 to 5 minutes. Use an ELISA reader to measure the absorbance of each sample and BSA standard at 562 nm and keep a record. Calculate the protein concentration in the sample by drawing a standard curve. Calculate the volume of loading buffer according to the concentration.

[0061] (4) Protein denaturation: Cook at 95-100℃ for 5-10 min. Immediately cool on ice for 5 min and store in a -80℃ refrigerator.

[0062] (5) Electrophoresis: Use 10% sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE), add the marker and protein sample to the sample tank, keep the voltage at 90V, and run the electrophoresis for 30 min. When the band moves from the upper gel into the lower gel and becomes a thin line, set the voltage to 120V. Stop the electrophoresis when the bromophenol blue in the sample moves to the bottom.

[0063] (6) Electrotransfer: Open the transfer clip and assemble the transfer clip from the negative electrode to the positive electrode in the order of sponge, filter paper, gel, nitrocellulose filter membrane (NC), filter paper, and sponge. Fix the transfer clip on the electrotransfer device and put it into the electrotransfer tank, and add the transfer solution. Connect the electrotransfer tank electrodes, keep the constant current at 400 mA, and electrotransfer for 40 minutes. Transfer the protein to the NC membrane.

[0064] (7) Blocking and antibody incubation: Place the membrane in 5% skim milk and block on a shaker for 120 minutes. After blocking, cut the membrane according to the position of the marker and the molecular weight of the target protein; place the membrane with the target protein in the corresponding primary antibody dilution and incubate it in a refrigerator at 4°C overnight. Wash with TBST solution 4 times, 10 minutes each time, remove the residual primary antibody dilution, place in the corresponding secondary antibody dilution, and incubate at room temperature for 60 minutes. Wash with TBST solution 8 times, 5 minutes each time.

[0065] (8) Exposure: Add luminescent solution and develop in a gel imager. Finally, use Image J software to analyze the signal.

[0066] 2.5PCR

[0067] First, use the reverse transcription kit to configure the system according to the instructions to reverse transcribe RNA into cDNA; second, use SYBR qPCR mixture to configure the mixture according to the instructions. Finally, amplify on the PCR instrument. -ΔΔCT The mRNA level of the target gene was calculated by the method and normalized with the mRNA level of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene to determine the fold change of the relative expression of the target gene.

[0068] ΔΔCT method:

[0069] A = CT (target gene, sample to be tested) - CT (internal standard gene, sample to be tested)

[0070] B = CT (target gene, control sample) - CT (internal standard gene, control sample)

[0071] K = AB expression multiple = 2 -K

[0072] 2.6 Statistical methods

[0073] This study used SPSS 25.0 software for statistical analysis of data. Indicates. For comparison between two groups, if the data of the two groups were normally distributed and had equal variance, the independent sample t test was used, otherwise the Mann-Whitney U rank sum test was used; for comparison between multiple groups, one-way analysis of variance was used for data with normal distribution and equal variance, and the LSD method was used for pairwise comparison between groups; otherwise the Kruskal-Wails test was used. P<0.05 was considered to be statistically different between groups, and P<0.01 and P<0.001 were considered to be statistically significant.

[0074] 3 Experimental results

[0075] 3.1 Xijiaqi prescription can improve the expression level of FTO / AMPK pathway-related molecular proteins

[0076] The molecular mechanism of Xijiaqi prescription in treating Dox-induced HF (heart failure) was explored. WB results showed that compared with the normal group, the protein expressions of FTO, AMPK, GLUT4, PFKFB3 and CPT1A in the myocardial tissue of mice in the model group were significantly decreased; compared with the model group, the protein expressions of FTO, AMPK, GLUT4, PFKFB3 and CPT1A in the myocardial tissue of mice in the low, medium and high dose groups of Xijiaqi prescription were significantly increased (e.g. Figure 1 Compared with the control group (Control), *** P<0.001; compared with the model group (Dox), # P<0.05, ## P<0.01, ### P<0.001. Low-dose group of Xijiaqi Fang (Dox+XJQ-L); medium-dose group of Xijiaqi Fang (Dox+XJQ-M); high-dose group of Xijiaqi Fang (Dox+XJQ-H).

[0077] 3.2 Xijiaqi prescription can increase the mRNA expression level of FTO / AMPK pathway-related molecules

[0078] The mRNA expression levels of FTO / AMPK pathway-related molecules in the myocardial tissue of each group of mice were detected. The results showed that compared with the control group, the mRNA expression level of FTO in the model group was significantly reduced, and after the intervention of Xijiaqi Fang, the mRNA levels of FTO in the Dox+XJQ-L, Dox+XJQ-M, and Dox+XJQ-H groups were significantly increased. At the same time, the mRNA levels of AMPK and its downstream molecules GLUT4, PFKFB3, and CPT1A also showed the same trend, which were significantly reduced in the Dox group, and their levels were increased after Xijiaqi Fang treatment (such as Figure 2 Compared with the control group (Control), *** P<0.001; compared with the model group (Dox), # P<0.05, ## P<0.01, ### P<0.001. Low-dose group of Xijiaqi Fang (Dox+XJQ-L); medium-dose group of Xijiaqi Fang (Dox+XJQ-M); high-dose group of Xijiaqi Fang (Dox+XJQ-H).

[0079] 4 Summary

[0080] This study explored the molecular mechanism of Xijiaqi prescription in treating HF and found that Xijiaqi prescription can increase the expression of FTO in the myocardial tissue of Dox-induced HF mice, while increasing the protein and mRNA levels of AMPK and its downstream key enzymes GLUT4, PFKFB3, CPT1A and other molecules, indicating that Xijiaqi prescription can improve Dox-induced HF by regulating the FTO / AMPK signaling pathway and its downstream molecules.

[0081] This study demonstrated that Xijiaqi prescription can improve doxorubicin-induced CHF by regulating the FTO / AMPK pathway, but its main active ingredients and specific molecular mechanisms need further study.

[0082] Example 2

[0083] 1 Experimental Materials

[0084] 1.1 Cell lines

[0085] In this experiment, the H9c2 rat cardiomyocyte cell line was purchased from the National Experimental Cell Resource Sharing Service Platform of the Institute of Basic Medicine, Chinese Academy of Medical Sciences.

[0086] 1.2 Drugs and reagents

[0087] The common reagents for the experiment are shown in the table below.

[0088]

[0089]

[0090]

[0091] 2 Experimental methods

[0092] 2.1 Cell culture

[0093] 2.1.1 Cell recovery

[0094] Preheat the complete culture medium in advance, add 9 mL of culture medium to a 15 mL centrifuge tube in the clean bench, take out the cells from the liquid nitrogen tank, quickly put the cryopreserved tube into a 37°C water bath to dissolve, and after it melts, use a pipette to transfer the frozen cells to the complete culture medium, centrifuge at 1000 r / min for 5 minutes. Pour out the supernatant in the clean bench, add 5 mL of complete culture medium again, mix gently by pipetting, and transfer to a 25 cm 2 The cells were placed in a cell culture flask and placed in a cell culture incubator for culture.

[0095] 2.1.2 Cell passaging

[0096] Take out the cells from the incubator and observe the cell morphology under a microscope. H9c2 cardiomyocytes are adherent cells with a normal spindle shape. Discard the original culture medium in the culture bottle in the clean bench, wash with PBS three times, add trypsin after absorbing the PBS, digest in the incubator for 1 minute, then observe under a microscope, the cell morphology becomes bright dots, add 3 times the complete culture medium to terminate the digestion, gently blow at all positions on the bottom of the culture bottle, transfer to a 15mL centrifuge tube and put into a centrifuge for centrifugation, centrifuge at 1000r / min for 5 minutes, discard the supernatant, resuspend the cell pellet with complete culture medium, pass the cells at a ratio of 1:2-5, and continue to culture the cells in the incubator.

[0097] 2.1.3 Cell cryopreservation

[0098] The steps before centrifugation are the same as cell passage. Prepare the cell freezing solution in advance. After centrifugation, resuspend the cell pellet with the cell freezing solution and freeze it in a -80℃ refrigerator or liquid nitrogen tank. Note the date and cell generation for future use.

[0099] 2.2 Cell modeling

[0100] A 6.25 μmol / L Dox solution was added to a 96-well plate with H9c2 cardiomyocytes and cultured for 24 h to construct a Dox-induced cardiomyocyte injury model.

[0101] 2.3 Construction and grouping of FTO overexpression / knockdown models in H9c2 cardiomyocytes

[0102] 2.3.1 Construction of FTO overexpression vector

[0103] 1. Gene information and target lentiviral vector

[0104] (1) Gene name: FTO; Species: Rat; Transcript ID: NM_001039713.

[0105] (2) Vector name: GV492.

[0106] (3) Element sequence: Ubi-MCS-3FLAG-CBh-gcGFP-IRES-puromycin.

[0107] 2. Vector digestion

[0108] Prepare 50 μL of enzyme digestion system according to the following list. Add various reagents in order according to the list, mix them by gently blowing with a pipette, centrifuge briefly, and place at 37℃ for 3 hours or overnight. Perform agarose gel electrophoresis on the vector digestion products to recover the target bands.

[0109] Components volume <![CDATA[ddH2O]]> 41μL 10×CutSmart Buffer 25μL Purified plasmid DNA (1 μg / μL) 2μL Xho I (10U / μL) 1μL Kpn I (10U / μL) 1μL Total 70μL

[0110] 3. Obtaining the target gene fragment

[0111] (1) PCR amplification of target gene fragment

[0112] (2) Exchange of PCR products and vectors

[0113] (3) Conversion

[0114] (4) Colony PCR Identification

[0115] The identified positive clone transformants were inoculated into an appropriate amount of LB liquid culture medium containing the corresponding antibiotics, cultured at 37°C for 12-16 hours, and an appropriate amount of bacterial liquid was taken for sequencing. The sequencing results were compared with the target gene sequence.

[0116] 4. Plasmid Extraction

[0117] Transfer the correctly sequenced bacterial solution to 10 mL of LB liquid culture medium containing the corresponding antibiotics, culture at 37°C overnight, use the kit to extract the plasmid, and extract the qualified plasmid into the downstream process. The detailed operation steps are as follows:

[0118] (1) Collect the overnight culture solution into a labeled 5 mL centrifuge tube and centrifuge at 12,000 rpm for 2 min to collect the bacteria.

[0119] (2) Discard the supernatant, add 250 μL of cell resuspension solution, and vortex thoroughly to ensure that the bacterial clumps are evenly suspended.

[0120] (3) Add 250 μL of cell lysis buffer and 10 μL of proteinase K, invert the tube 5 to 6 times, and gently mix; let it stand for 1 to 2 minutes to allow the cells to lyse and clarify.

[0121] (4) Add 350 μL of neutralizing solution, mix by inverting to completely precipitate the protein, and place on ice for 5 min.

[0122] (5) Centrifuge at 10,000 rpm for 10 min, discard the protein, and collect the supernatant into another clean, sterile 1.5 mL EP tube.

[0123] (6) Centrifuge at 12,000 rpm for 5 min. Prepare a labeled recovery column and transfer the supernatant to the recovery column. Centrifuge at 12,000 rpm for 1 min and discard the waste liquid below.

[0124] (7) Add 600 μL of pre-prepared rinse solution, centrifuge at 12,000 rpm for 1 min, discard the lower layer of waste liquid, repeat once, and centrifuge at 12,000 rpm for 2 min to further remove the residual rinse solution.

[0125] (8) Transfer the recovery column to a new 1.5 mL EP tube in a clean bench, let it stand for 10 to 20 minutes, and allow it to dry naturally.

[0126] (9) Add 95 μL Nuclease-Free Water to the recovery column, let it stand for 2 min, centrifuge at 12,000 rpm for 2 min, collect the samples, number them, perform electrophoresis, measure the concentration, and conduct quality inspection.

[0127] 5. Lentiviral packaging

[0128] Construct a lentiviral packaging system and transfect 293T cells with plasmids. Harvest the virus 48 to 72 hours after transfection (i.e., unpurified cell supernatant), concentrate and purify to obtain a high-titer lentiviral storage solution, and finally measure various indicators of the lentivirus according to strict quality standards.

[0129] 2.3.2 Construction of FTO knockdown vector

[0130] (1) Vector name: GV493.

[0131] (2) Element sequence: hU6-MCS-CBh-gcGFP-IRES-puromycin.

[0132] (3) Control insert sequence: TTCTCCGAACGTGTCACGT (SEQ ID NO: 1).

[0133] (4) The general steps are the same as those for the construction of the overexpression vector; however, based on the target gene sequence, multiple RNAi target sequences are designed according to the RNAi sequence design principles, as shown in the table below, and the target PSC97741 with the best kinetic parameters is selected to enter the subsequent experimental process.

[0134]

[0135]

[0136] 2.3.3 Construction of FTO overexpression model / knockdown model

[0137] Generally, virus transfection is performed when the cell confluence is 30-50%. H9c2 cardiomyocytes are plated in a 6-well plate in advance. According to the calculated MOI value, appropriate amount of virus and transfection reagent are added to the cells. After gently mixing, the culture dish is gently shaken to ensure that the mixed solution is evenly distributed. The culture dish is returned to the incubator. After 16 hours of culture, the medium is changed to DMEM medium containing 10% fetal bovine serum, and culture is continued for 48 hours as needed. RNA and protein are subsequently extracted according to experimental needs.

[0138] 2.3.4 Cell Grouping

[0139] The cells are grouped as follows:

[0140] (1) FTO knockdown experiment: The cells were divided into two groups, FTO knockdown negative control group (ShNC) and FTO knockdown group (ShFTO);

[0141] (2) FTO overexpression experiment: The cells were divided into two groups, FTO overexpression negative control + Dox group (OE-NC+Dox) and FTO overexpression + Dox group (OE-FTO+Dox).

[0142] 2.4WB

[0143] The method is the same as in Example 1.

[0144] 2.5PCR

[0145] The method is the same as in Example 1.

[0146] 2.6 Statistical methods

[0147] This study used SPSS 25.0 software for statistical analysis of data. Indicates. For comparison between the two groups, if the data of the two groups were normally distributed and the variances were equal, the independent sample t test was used, otherwise the Mann-Whitney U rank sum test was used, with P < 0.05 indicating that there was a statistical difference between the groups, P < 0.01, P < 0.001 indicating that the data had a significant statistical difference.

[0148] 3 Experimental results

[0149] 3.1 Dox can downregulate the expression of AMPK and its downstream key enzymes GLUT4, PFKFB3, and CPT1A mRNA

[0150] Firstly, the expression of AMPK and its downstream key enzymes mRNA in H9c2 cardiomyocytes of the control group and the model group was detected. The results showed that compared with the blank group, the mRNA level of AMPK in the Dox group was significantly decreased, and the mRNA expressions of its downstream GLUT4, 6-phosphofructo-2-kinase / fructose-2,6-biopgosphatase 3 (PFKFB3), and carnitine palmitoyl transferase 1A (CPT1A) were also significantly decreased (e.g. Figure 3 Compared with the Control group, *** P<0.001; Dox, model group.

[0151] 3.2 Dox can downregulate the expression of AMPK and its downstream key enzymes GLUT4, PFKFB3, and CPT1A proteins

[0152] In addition, the protein level was verified, and the results showed that compared with the blank group, the AMPK protein level in the Dox group was significantly reduced, and the protein expressions of its downstream GLUT4, PFKFB3, and CPT1A were also significantly reduced (such as Figure 4 Compared with the Control group, *** P<0.001; Dox, model group.

[0153] 3.3FTO knockdown can inhibit AMPK activation

[0154] To further verify the relationship between FTO and AMPK, the expression of AMPK after FTO knockdown was detected. Figure 5 As shown in the figure, when FTO was knocked down, the protein expression of AMPK was significantly downregulated, and the difference was statistically significant. Compared with the FTO knockdown negative control group (ShNC), *** P<0.001; ShFTO: FTO knockdown group.

[0155] 3.4FTO overexpression can upregulate Dox-induced decreased AMPK expression

[0156] In addition, overexpression verification was performed on H9c2 cardiomyocytes. The study found that compared with the FTO overexpression negative control, under the same conditions of Dox intervention, the protein expression of AMPK in the OE-FTO+Dox group was significantly upregulated (e.g. Figure 6 The difference was statistically significant, indicating that FTO overexpression significantly upregulated the expression of AMPK protein, which was reduced after Dox induction. Compared with the FTO overexpression negative control group (OE-NC), * P<0.05; OE-FTO, FTO overexpression group.

[0157] 4 Summary

[0158] Experiments have confirmed that Dox can downregulate the expression of AMPK and its downstream key enzymes GLUT4, PFKFB3, and CPT1A. Previous MeRIP-seq analysis after FTO knockdown showed that FTO-mediated RNAm6A methylation was mainly enriched in the AMPK pathway. Further studies found that FTO knockdown can inhibit AMPK activation, while FTO overexpression can reverse the Dox-induced decrease in AMPK expression. These results indicate that FTO may be a key upstream molecule of AMPK. Inhibition of the FTO / AMPK pathway may be an important mechanism of Dox-induced cardiotoxicity.

[0159] AMPK can stimulate the breakdown of macromolecules to generate energy, and the pathways of stimulation include increasing glucose utilization and mobilizing lipid storage. AMPK stimulates glucose utilization by phosphorylating targets involved in glucose transporter transport, thereby increasing cellular glucose uptake. AMPK also increases flux through the glycolytic pathway by phosphorylating PFKFB3, which affects the activity of fructose phosphate kinase 1 (PFK1), which is the rate-limiting enzyme in glycolysis. In addition to stimulating glucose utilization, AMPK also promotes cells to utilize lipid reserves. This is mainly achieved by stimulating lipase to release fatty acids from triglyceride stores. The free fatty acids are then imported into the mitochondria for β-oxidation. The entry of fatty acids into the mitochondria requires the transport system of carnitine palmitoyl transferase 1 (CPT1), and CPT1 activity is also regulated by AMPK activity. Fatty acid oxidation can provide energy when energy is scarce. When fatty acids are absorbed across the plasma membrane, they are activated into fatty acyl-CoA, which can be stored or oxidized.

[0160] Inhibition of the FTO / AMPK pathway may be an important molecular mechanism of Dox-induced cardiotoxicity. Dox may lead to inactivation of the FTO / AMPK signaling pathway, reduce glucose uptake and fatty acid oxidation, cause insufficient ATP production, and thus lead to HF. Xijiaqi prescription can improve doxorubicin-induced CHF by regulating the FTO / AMPK pathway.

[0161] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0162] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. The use of a Siegesbeckia oxyphylla composition in the preparation of a product for improving the expression level of cardiac FTO, characterized in that: The Siegesbeckia composition is prepared from 38-42 parts by weight of astragalus, 8-12 parts by weight of siegesbeckia herb and 2-3 parts by weight of cortex perillae.

2. The use according to claim 1, characterized in that: The increasing the expression level of cardiac FTO includes increasing the mRNA level of FTO and increasing the protein level of FTO.

3. The use according to claim 1, characterized in that: The Siegesbeckia composition is prepared from 40 parts by weight of Astragalus, 10 parts by weight of Siegesbeckia herb and 2.5 parts by weight of Perennial Perennial Bark.

4. Use of the Siegesbeckia composition of claim 1 in the preparation of a product for increasing the expression level of genes related to the cardiac AMPK pathway, characterized in that: The AMPK pathway related genes are one or more of AMPK, GLUT4 and PFKFB3.

5. The use according to claim 4, characterized in that: The Siegesbeckia scoparia composition increases the expression level of the AMPK pathway-related genes by increasing the expression level of cardiac FTO.

6. The use according to claim 4, characterized in that: The increasing the expression level of the cardiac AMPK pathway-related gene includes increasing the mRNA level of the AMPK pathway-related gene and increasing the protein level of the AMPK pathway-related gene.

7. The use according to any one of claims 1 to 6, characterized in that: The product is a pharmaceutical preparation.

8. The use according to claim 7, characterized in that: The pharmaceutical preparation comprises pharmaceutically acceptable excipients.

9. The use according to claim 7, characterized in that: The dosage form of the pharmaceutical preparation is tablet, capsule, granule, oral solution or injection.

Citation Information

Patent Citations

  • Herba siegesbeckiae composition and application of herba siegesbeckiae composition in preparation of medicine for improving heart failure after myocardial infarction

    CN117815286A

  • Application of wogonoside in preparation of medicine for preventing and treating chronic heart failure

    CN118340791A